NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
January 23 2023 - 9:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial
availability of DPNCheck 2.0, the Company's latest point-of-care
device that leverages gold-standard nerve conduction technology to
detect peripheral neuropathy. DPNCheck 2.0 provides rapid patient
screening with quantitative measurement of peripheral nerve
function. It features an easy-to-use touchscreen, onboard
step-by-step instructions, improved temperature compensation,
real-time nerve response display and other enhancements. Its
companion software facilitates clinical documentation of test
results. Cloud-based aggregation of population-health data and
integration with provider EHR systems is planned for later this
year.
Peripheral neuropathy, the systemic degeneration of peripheral
nerves, is a common and debilitating condition that may affect up
to 30% of the Medicare-aged population. An increasing number of
healthcare providers and health plans that support the Medicare
population have recently turned their attention to early detection
and management of this condition to help reduce their patients’
risk of foot ulcers, falls, pain and other complications. By
incorporating screening for peripheral neuropathy using nerve
conduction technology, it is possible to uncover elevated risk for
these complications earlier and more accurately than traditional
clinical approaches such as the monofilament and tuning fork
tests.
“For more than a decade, our first-generation DPNCheck device
has been used and trusted by thousands of providers to assess over
2-million patients,” said Shai N. Gozani, M.D., Ph.D., Chief
Executive Officer, NeuroMetrix. “We are excited to launch our
newest version to even better address the needs of our clinical
partners. We’ve opened the door to more widespread screening with a
user-friendly design that makes it faster and easier for care
organizations to roll out and train their point-of-care staff and
deploy testing.”
DPNCheck 2.0 will be presented at the Medicare Advantage
Leadership Innovations National Conference January 24-25, 2023 at
the Renaissance Glendale, AZ. Please visit Neurometrix booth #21 to
see the device in action and learn more from NeuroMetrix’s
value-based care and population health experts. For more
information, visit www.DPNCheck.com.
About NeuroMetrix
NeuroMetrix is an innovation-driven company with a mission to
improve individual and population health through novel medical
devices and technology solutions for neurological disorders and
pain syndromes. The Company has three commercial products.
DPNCheck® is a diagnostic device that provides rapid, point-of-care
detection of peripheral neuropathies. ADVANCE® is a diagnostic
device that provides automated, in-office nerve conduction studies
for the evaluation of focal neuropathies. Quell® Fibromyalgia is a
wearable neuromodulator that is the first and only FDA-authorized
medical device to help reduce the symptoms of fibromyalgia. For
more information, visit www.neurometrix.com.
Source: NeuroMetrix, Inc.
Thomas T. Higgins SVP and Chief Financial Officer 781-314-2761
neurometrix.ir@neurometrix.com
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/aee7be42-c171-4ca3-90f7-e46344542209
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Mar 2024 to Apr 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Apr 2023 to Apr 2024